BiotechTube

JBT-101 (lenabasum)

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis

Trial Timeline

Sep 29, 2015 → Dec 28, 2016

NCT ID
NCT02465450

About JBT-101 (lenabasum)

JBT-101 (lenabasum) is a phase 2 stage product being developed by Corbus Pharmaceuticals for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02465450. Target conditions include Cystic Fibrosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02465450Phase 2Completed

Competing Products

20 competing products in Cystic Fibrosis

See all competitors
ProductCompanyStageHype Score
VX-522 mRNA therapy + IVAModernaPhase 1/2
38
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
44
Enfortumab VedotinAstellas PharmaPhase 2
52
CefiderocolShionogiApproved
85
LenvatinibEisaiPhase 2
52
Lenvatinib + PembrolizumabEisaiPhase 2
52
CREONAbbVieApproved
85
Pancrelipase + PancrelipaseAbbVieApproved
85
Creon IR + Creon® (DR/GR)AbbViePhase 2
52
ABBV-CLS-628 + PlaceboAbbViePhase 2
52
Elagolix + PlaceboAbbViePhase 2
52
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222AbbViePhase 2
52
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119AbbViePhase 2
52
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD5634 for inhalation + AZD5634 for infusionAstraZenecaPhase 1
33
Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3
77
AZD1236 + PlaceboAstraZenecaPhase 2
52
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3
77
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part BAstraZenecaPhase 1
33
AZD9668 + AZD9668 Placebo equivalentAstraZenecaPhase 2
52

Other Products from Corbus Pharmaceuticals

Lenabasum 5 mg + Lenabasum 20 mgPhase 3
69
Lenabasum 20 mg + Lenabasum 5 mg + PlaceboPhase 3
69
JBT-101 + PlaceboPhase 2
44
Lenabasum 20 mg + Lenabasum 5 mgPhase 2
44
JBT-101 + Placebo + Part B Open-Label ExtensionPhase 2
44